期刊
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
卷 55, 期 1, 页码 131-142出版社
SCIENCE PRESS
DOI: 10.3724/abbs.2022154
关键词
obesity; swertiamarin; fat browning; energy expenditure; fatty acid oxidation
This study demonstrates the therapeutic effects of Swertiamarin (STM) on preventing obesity and its associated metabolic diseases. STM improves energy expenditure, promotes fat browning, and reduces fat deposition in mice with preexisting obesity. These findings suggest that STM may serve as a potential therapy for obesity.
Obesity is a risk factor for many metabolic diseases. Efficient therapeutic strategies are urgently needed. Swertiamarin (STM) prevents obesity and the associated insulin resistance and inflammation. However, the therapeutic effects of STM on preexisting obesity remain unclear. Therefore, in this study we aim to investigate the effects of STM on energy expenditure and fat browning in mice with preexisting obesity. C57BL/6J mice are fed with a high-fat diet (HFD) for 8 weeks to induce obesity and then gavaged (or not) with STM for 10 weeks. The whole-body energy metabolism of mice is examined by indirect calorimetry. The results show that after 10 weeks of treatment, STM markedly prevents HFD-induced weight gain, chronic inflammation, insulin resistance, and hepatic steatosis. STM promotes oxygen consumption and energy expenditure. The level of uncoupling protein 1 is enhanced in the brown and white adipose tissues of STM-treated mice. STM increases the phosphorylation of AMP-activated protein kinase and the expressions of genes involved in fat oxidation, reducing fat deposition in skeletal muscles. Meanwhile, STM does not affect the intestinal microbiotic composition. Overall, STM supplementation may serve as a potential therapy for obesity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据